Cargando…
Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications—a methodological review
BACKGROUND: An accurate and comprehensive assessment of harms is a fundamental part of an accurate weighing of benefits and harms of an intervention when making treatment decisions; however, harms are known to be underreported in journal publications. Therefore, we sought to compare the completeness...
Autores principales: | Paludan-Müller, Asger S., Créquit, Perrine, Boutron, Isabelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8028762/ https://www.ncbi.nlm.nih.gov/pubmed/33827569 http://dx.doi.org/10.1186/s12916-021-01955-0 |
Ejemplares similares
-
Published trials of TACE for HCC are often not registered and subject to outcome reporting bias
por: Grégory, Jules, et al.
Publicado: (2020) -
Avoidable waste of research related to outcome planning and reporting in clinical trials
por: Yordanov, Youri, et al.
Publicado: (2018) -
Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments
por: Winstone, Julie, et al.
Publicado: (2015) -
Redefining Risk Stratification and Endpoints for Clinical Trials in Kidney Transplantation: Rationale and Methodology of Proposals Submitted to the European Medicines Agency by the European Society for Organ Transplantation
por: Naesens, Maarten, et al.
Publicado: (2022) -
Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis
por: Munkholm, Klaus, et al.
Publicado: (2019)